10:56 AM EDT, 05/31/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Friday that its recombinant ADAMTS13 has received approval recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use to treat ADAMTS13 deficiency in children and adults with congenital thrombotic thrombocytopenic purpura, or cTTP.

The committee's decision was based on the company's crossover phase 3 trial in cTTP, a chronic blood clotting disorder due to a deficiency in the ADAMTS13 enzyme, Takeda added.

The European Commission will now evaluate the committee's opinion for rADAMTS13's potential marketing authorization across the European Union, the company said.

Takeda's stock rose 1.8% in recent trading.

Price: 13.27, Change: +0.24, Percent Change: +1.80